Download A4Medicine Mobile App
Empower Your RCGP AKT Journey: Master the MCQs with Us! 🚀
Octreotide is a synthetic analogue of somatostatin, a hormone that plays a key role in regulating the digestive system. Its primary use in the context of malignant bowel obstruction (MBO) is for symptom management, particularly in patients with advanced cancer where the obstruction is inoperable. Octreotide effectively reduces gastrointestinal secretions and motility, helping to alleviate distressing symptoms such as nausea, vomiting, and abdominal pain. Its role in palliative care is significant, offering improved quality of life for patients facing the complex challenges of MBO due to malignancy.
While it is not a curative treatment, octreotide's ability to manage symptoms makes it a valuable component of comprehensive care in advanced cancer patients.
| Aspect | Details |
|---|---|
| Indication | Management of symptoms in malignant bowel obstruction (MBO), especially in advanced cancer cases. |
| Mechanism of Action | Somatostatin analogue; reduces gastrointestinal secretions, motility, and blood flow, thereby alleviating symptoms of obstruction. |
| Dosage and Administration | Typically initiated at low doses (e.g., 100-300 μg/day) and adjusted based on symptom control and tolerance. Administered subcutaneously or intravenously ( See BNF instructions below ) |
| Efficacy | Effective in reducing symptoms like nausea, vomiting, and abdominal pain in patients with MBO. |
| Side Effects | May include bradycardia, hypoglycemia, hypo/hyperglycemia, abdominal cramps, fatigue, and steatorrhea.... |
Try our Free Plan to get the full article.
